Results 161 to 170 of about 73,988 (260)

Real‐World Evidence of the Effectiveness and Safety of Biosynthetic Semaglutide in Type 2 Diabetes: A Multicentre Study From Pakistan

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the real‐world effectiveness, safety and patient‐reported outcomes of biosynthetic semaglutide in adults with type 2 diabetes mellitus (T2DM) receiving routine outpatient care in a cost‐constrained setting. Methods This 30‐week, prospective, multicentre, non‐interventional study enrolled adults with T2DM initiating ...
Arshad Hussain   +9 more
wiley   +1 more source

Liver Fibrosis Estimated Using Noninvasive Blood Biochemical Indices Is Correlated with Visit-to-Visit Glycated Hemoglobin A1c Variability in Individuals with Type 2 Diabetes. [PDF]

open access: yesBiomedicines
Kaneko Y   +13 more
europepmc   +1 more source

Impact of Autoimmune Hypothyroidism and Celiac Disease on Progression to Diabetes in Individuals Positive for GAD65 or IA‐2 Autoantibodies

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess whether autoimmune hypothyroidism (AH) or celiac disease (CD) influences diabetes progression among individuals who tested positive on a pooled screening assay for glutamic acid decarboxylase 65 and insulinoma‐associated protein 2 autoantibodies (GADA/IA‐2A).
Afif Nakhleh   +4 more
wiley   +1 more source

GLP‐1‐Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris   +5 more
wiley   +1 more source

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

open access: yes
Diabetes, Obesity and Metabolism, EarlyView.
Juan Manuel Arteaga‐Diaz   +4 more
wiley   +1 more source

Efficacy and Safety of Intensifying Once‐Weekly Insulin Icodec Treatment With Once‐Weekly Semaglutide in Adults With Type 2 Diabetes: A Single‐Arm, Open‐Label, Treat‐to‐Target, Phase 3b Trial (ONWARDS 8)

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To investigate the efficacy and safety of intensifying once‐weekly insulin icodec (icodec) with once‐weekly semaglutide in adults with type 2 diabetes (T2D). Materials and Methods ONWARDS 8 was a single‐arm, open‐label, treat‐to‐target, Phase 3b trial comprising a 26‐week icodec run‐in period and a 26‐week semaglutide intensification ...
Krzysztof Strojek   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy